LONGTERM INTRACAVERNOUS (IC) THERAPY RESPONDERS CAN POTENTIALLY SWITCH TO SILDENAFIL CITRATE AFTER RADICAL PROSTATECTOMY (RP)

Rupesh Raina, M.D., Sandra Ausmundson, R.N., Ashok Agarwal, Ph.D., Milton Lakin, M.D., Craig D Zippe, M.D.

36 patients (mean age 60.9 yrs) with erectile dysfunction (ED) following RP were identified as long-term users (mean 2.5 yrs) of IC injection; (PG E1 61%, Trimex 39%). The SHIM (IIEF-5) was used to assess outcomes. The 36 patients received sildenafil orally (50-100mg) for a minimum of 5 attempts. 41% (15/36) of patients successfully switched to sildenafil (mean SHIM of 12.5) and discontinued IC injection. 38% (14/36) found sildenafil ineffective and 19% (7/36) used it to enhance IC injections. Long-term users of IC injection therapy can potentially switch to sildenafil citrate with acceptable sexual satisfaction. It appears that a mean SHIM score of 12.5 is required for a successful switch to oral therapy.